title: Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis.
abstract: OBJECTIVE
  Pegylated interferon (peg-IFN) and ribavirin (RBV) treatment is less effective in patients with hepatitis C virus (HCV) and liver cirrhosis than in non-cirrhotic patients. Many patients with advanced liver disease have been excluded from the pivotal randomized controlled studies. The aim of this study was to investigate the efficacy and tolerability of combination therapy in unselected patients with Child-Pugh Class A liver cirrhosis at a Swedish university clinic.
  
  
  METHODS
  The virologic response and adverse events were retrospectively analyzed in 104 patients with HCV-associated Child-Pugh Class A liver cirrhosis who had been treated with peg-IFN and RBV.
  
  
  RESULTS
  Overall sustained virologic response (SVR) was achieved in 13% genotype 1-, 60% genotype 2-, and 31% genotype 3-infected patients. In treatment-naive patients, the corresponding rates were 13%, 82%, and 38%, respectively. In 46% of patients, treatment was discontinued prematurely owing to lack of virologic response in the majority.
  
  
  CONCLUSIONS
  SVR rates found in our study, in particular for genotype 1 patients (13%), were lower than those generally found in randomized controlled studies. For cirrhotic patients, new treatment alternatives are urgently needed to improve treatment outcome.
authors.affiliation: Department of Gastroenterology and Hepatology, Karolinska University Hospital, Sweden.
authors.forename: Eliya
authors.initials: E
authors.lastname: Syed
authors.forename: Nogol
authors.initials: N
authors.lastname: Rahbin
authors.forename: Ola
authors.initials: O
authors.lastname: Weiland
authors.forename: Tony
authors.initials: T
authors.lastname: Carlsson
authors.forename: Antti
authors.initials: A
authors.lastname: Oksanen
authors.forename: Markus
authors.initials: M
authors.lastname: Birk
authors.forename: Loa
authors.initials: L
authors.lastname: Davidsdottir
authors.forename: Karin
authors.initials: K
authors.lastname: Hagen
authors.forename: Rolf
authors.initials: R
authors.lastname: Hultcrantz
authors.forename: Soo
authors.initials: S
authors.lastname: Aleman
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a